A Careful, Honest Comparison

ChondroFiller® vs ACI

ACI is the original two-stage autologous chondrocyte implantation, largely superseded in modern practice by MACI but still encountered in older literature and some centres. ChondroFiller® is a single-stage scaffold injection. Here is the honest comparison.

Illustration of ChondroFiller injected under ultrasound guidance to coat the worn cartilage surface of the knee
  1. Collagen scaffold
  2. Ultrasound-guided injection
  3. Coats the worn surface

ChondroFiller®

A collagen scaffold injected under ultrasound guidance. It sets in minutes and coats the worn cartilage so your own cells can lay down new tissue.

Illustration of cartilage cells harvested, grown in a laboratory and implanted under a sewn patch
  1. Cartilage harvested
  2. Cells grown in a laboratory
  3. Implanted under a patch

ACI

Two surgeries: cartilage cells are harvested, grown in a laboratory, then implanted under a patch over the defect.

Quick answer

ChondroFiller® is a single-stage scaffold injection; ACI is the original two-stage cell-based surgical implant under a periosteal patch. ACI (autologous chondrocyte implantation) was the first commercial cell-based cartilage repair technique, originally published in 1994. It involves a cartilage biopsy, several weeks of laboratory cell culture and a second surgery to inject the cells under a periosteal flap sewn over the defect. Most centres have moved to MACI, which uses a collagen membrane instead of periosteum and has fewer complications. ChondroFiller® offers a different alternative again: a single-stage scaffold injection with no cell harvest, no second surgery, no upper age limit and no defect-size limit on the injection.

How it works

ChondroFiller® vs ACI: the key difference

ACI is a two-stage cell-based surgical technique: cartilage cells are harvested at an arthroscopy, cultured in a laboratory for four to six weeks and then injected as a suspension under a periosteal patch sewn over the defect at a second open operation. ChondroFiller® takes a different approach: a sterile collagen scaffold is placed in a single ultrasound-guided injection, and the body’s own cells migrate in over six to twelve months. No periosteal patch. No two-stage surgery. No laboratory phase.

How each treatment works

ChondroFiller®

Illustration of ChondroFiller injected under ultrasound guidance to coat the worn cartilage surface of the knee

ChondroFiller® is a sterile type I collagen scaffold. At London Cartilage Clinic it is injected as a liquid into the joint under ultrasound guidance, where it sets within minutes and coats the worn cartilage at the load-bearing surfaces, from a contained focal defect to diffuse surface wear.

The patient’s own cells then migrate into the scaffold and lay down new cartilage matrix over six to twelve months. Single-stage. No cell harvest. No lab phase. No periosteal harvest.

ACI

Illustration of cartilage cells harvested, grown in a laboratory and implanted under a sewn patch

ACI requires two surgeries. First, an arthroscopy harvests a small piece of cartilage from a non-weight-bearing area. The chondrocytes are sent to a specialist laboratory and expanded in culture for four to six weeks.

A second open or mini-open surgery follows: a piece of periosteum is harvested (usually from the tibia) and sewn over the prepared defect, and the cultured chondrocytes are injected as a suspension under the patch to mature into new cartilage.

Looking ahead

What can you expect over time?

ChondroFiller®

Tissue formation over 6–12 months

Published ChondroFiller® cohorts show maintained outcomes (IKDC, Harris Hip Score, MOCART MRI) at five years and beyond in suitable focal defects.

ACI

Long-term published cohorts to 10–15 years

ACI has the longest cell-based cartilage-repair publication history, with cohorts out to ten and fifteen years. The headline durability is good in selected patients, but longer-term ACI series report higher rates of graft hypertrophy and reoperation than modern MACI techniques.

Read the comparison in context

Direct duration comparison is partly historical. Most centres that offer cell-based implantation today use MACI rather than first-generation ACI, because the membrane-based approach has fewer complications.
Explore the ChondroFiller evidence →

Your treatment plan

Number of injections

ChondroFiller®

Typically one injection course, with the box quantity (one, two or three) decided from MRI. ChondroFiller® can be repeated for a separate new defect if needed.

ACI

ACI is a one-off two-stage course. A repeat would require a fresh cartilage biopsy and full cell expansion again. Revision surgery for periosteal hypertrophy is sometimes needed in the months and years after the original procedure.

The treatment journeys

ChondroFiller® pathway

  1. 1

    Suitability and MRI review

    Professor Lee reviews your MRI and examination to confirm the injection fits your defect and how many boxes are needed.
  2. 2

    One outpatient injection

    Delivered in 30 to 45 minutes under ultrasound guidance and local anaesthetic, with the gel setting in minutes.
  3. 3

    Home within the hour

    There is no brace or crutches unless your medical team specifies otherwise, and a free telephone review follows at six weeks.

ACI pathway

  1. 1

    First surgery: cartilage biopsy

    An arthroscopy harvests a small piece of cartilage from a non-weight-bearing area, and the chondrocytes are expanded in a laboratory for four to six weeks.
  2. 2

    Second surgery: periosteal patch

    A piece of periosteum is sewn over the prepared defect and the cultured chondrocytes are injected under it as a suspension.
  3. 3

    Maturation and possible revision

    The cells mature into new cartilage, and revision surgery for periosteal hypertrophy is sometimes needed in the months and years afterwards.

Care and precautions

Understanding the risks

BEFORE · DURING · AFTER

Sterile technique.
Image guidance.
Clear aftercare.

Very different risk profiles. ChondroFiller® at London Cartilage Clinic is an ultrasound-guided outpatient injection with routine IV antibiotic cover. The most serious risk is joint infection, which is rare.

ACI involves two surgeries with the standard surgical risks (infection, deep-vein thrombosis, anaesthetic complications) at each operation, plus procedure-specific issues: periosteal hypertrophy (overgrowth of the patch requiring reoperation), graft delamination, donor-site morbidity at the periosteum and a prescriptive rehabilitation programme. These were the main drivers behind the field moving from ACI to MACI.

Practical planning and safety

Questions to raise before either option

Ask about temporary soreness or swelling, the risk of joint infection, and anything specific to your health and current medicines. Ask who you contact if something does not feel right afterwards.

Who may suit ChondroFiller →

Aftercare depends on the route

After the ChondroFiller injection there is no brace and no crutches unless your medical team specifies otherwise. Keyhole surgery follows the rehabilitation protocol set out by the manufacturer, with a brace for 48 hours and weight rebuilt over about six to eight weeks.

Read the injection aftercare guide →

Your joint, your goals

Where does each option fit?

Professor Lee reviewing a knee scan
Your symptoms, scans and goals guide the decision.

ACI is appropriate for symptomatic knee cartilage defects in adults with otherwise reasonably preserved joints, in centres still offering the procedure. In modern practice, MACI is usually offered in preference to ACI for the same indications. If you have been recommended ACI specifically, it is worth asking whether MACI is an option at the same centre.

ChondroFiller® is appropriate for cartilage wear in the joint, whether a contained focal defect or diffuse surface wear, with no upper age limit and no defect-size limit on the injection. It is delivered as an injection, which suits patients who want to avoid open surgery, a periosteal patch and a two-stage pathway. See who is suitable for ChondroFiller?

What would make the difference for you?

Questions worth taking to your consultation, so the discussion stays on your joint.

  1. 01What is causing my joint pain?The diagnosis and your imaging decide which treatments are worth discussing.
  2. 02Is there a defect, or wear across the joint?Ask how the pattern of cartilage damage shapes the recommendation.
  3. 03What improvement are we aiming for?Agree realistic goals for pain, function and timescale before you choose.
  4. 04What happens if I need more help later?Ask which options stay open if symptoms return or progress.
Arrange a discovery call

Planning the cost

Compare the complete care package

Ultrasound-guided injection

ChondroFiller®

From · one box

£3,000

Two boxes £5,500; three boxes £8,000. The consultation is charged separately.

Full ChondroFiller pricing →

At London Cartilage Clinic, ChondroFiller® costs from £3,000 for one box, £5,500 for two and £8,000 for three, with the consultation charged separately. See the ChondroFiller® cost guide.

Where ACI is still offered privately it typically costs £25,000 to £35,000 in the UK because the cell processing and two surgeries are inherently expensive. NHS availability of ACI specifically is now very limited; most NHS centres have moved to MACI for cell-based cartilage repair.

The headline cost gap is meaningful, but the more important question is whether a cell-based two-stage operation or a single-stage scaffold injection is the right answer for the defect on imaging.

Making a recommendation

When each option may make sense

ChondroFiller®

A discussion to have

  • A focal cartilage defect on MRI where a single-stage scaffold injection is reasonable.
  • You want to avoid a two-stage operation, periosteal harvest and the historical complications of ACI.
  • You are looking at a private-pay cell-based pathway and want to understand the alternatives.

ACI

A discussion to have

  • ACI is increasingly recommended only in specific centres where the surgeon has long experience with the technique and a particular reason to prefer it over MACI.
  • For most patients considering a cell-based cartilage implant, MACI is the more current option: see ChondroFiller® vs MACI for that comparison.

Choosing another path

When another approach may be better

ChondroFiller®

A reason to reconsider

  • Very large or multi-zone defects where a surgical cell-based or co-delivery procedure is more appropriate.
  • Unstable subchondral bone, significant bone marrow oedema or a joint where imaging review points to replacement; bone-on-bone wear on its own is not the deciding factor.

ACI

A reason to reconsider

  • Small focal defects where a two-stage cell-based pathway is over-treatment.
  • Most modern indications, where MACI is the preferred cell-based option over original ACI.
  • Patients unwilling to accept the periosteal-patch-specific risks or unable to complete the rehabilitation programme.

The bottom line

ACI was the original cell-based cartilage-repair technique and still has a place in specialist centres, but modern practice has largely moved on to MACI for the same indications. ChondroFiller® offers a different alternative again: a single-stage scaffold injection without cell harvest, periosteal patch or two-stage surgery. The right answer is decided from imaging and a clear conversation about trade-offs, not from a default label.

Common questions

01

What is the difference between ACI and MACI?

ACI is the original technique: cultured cartilage cells injected as a suspension under a periosteal patch sewn over the defect. MACI is the modern variant: the same cultured cells are pre-loaded onto a porcine collagen membrane and the membrane is implanted into the defect. MACI was developed to reduce the periosteal-patch-specific complications of ACI.

02

Should I have ACI today, or is it outdated?

ACI is still offered in specific specialist centres, but in modern UK practice MACI is usually preferred for the same indications. If ACI specifically has been recommended to you, it is worth asking whether MACI is available at the same centre, and what the rationale is for ACI over MACI in your case.

03

Is the donor-site morbidity from the periosteum a real concern?

It is a recognised issue in published ACI series: pain at the periosteal harvest site and occasional functional impact. It is one of the reasons MACI, which uses a collagen membrane instead of harvested periosteum, became the more common cell-based technique. ChondroFiller® avoids the question entirely because there is no harvest.

04

Can ChondroFiller® be used after ACI has failed?

Sometimes yes: where the failed ACI has left a contained defect with reasonably stable surrounding tissue and no significant overgrowth or bony irregularity, ChondroFiller® can occasionally be considered. We review the post-ACI imaging before deciding.

05

How does the long-term evidence compare?

ACI has the longest cell-based cartilage-repair publication history because it was the first commercially available technique, with cohorts out to ten and fifteen years. ChondroFiller® has a younger publication record, with maintained outcomes (IKDC, Harris Hip Score, MOCART MRI) at five years and over 19,000 cases of clinical use across joints. See the ChondroFiller® clinical evidence page.

06

Why would I choose ChondroFiller® over the cell-based options?

For some patients, the single-stage scaffold injection avoids the two-stage surgical pathway, the cell-harvest step, the periosteal patch (in ACI) and the cost of cell processing. For other patients, particularly with larger or more demanding defects, a cell-based pathway is the better answer. The decision is made at consultation with imaging review.

Book a ChondroFiller® Assessment in London

Natural cartilage regeneration starts with the right defect, the right operator, and the right plan. Start with a free call, or book a consultation with Professor Lee at our Harley Street clinic.
Privacy & Cookies PolicyTerms & ConditionsFeedback & Complaints
Free Discovery Call